[Dysimmune and inflammatory myopathies].
Dysimmunes and inflammatory myopathies (DIM) are divided in four groups, on the grounds of clinical and histopathological criteria: dermatomyositis, polymyositis, inclusion body myositis and autoimmune necrotizing myopathy. They may present as unique condition (primary DIM), or in association with cancer (paraneoplastic DIM) or connective tissue disease (overlap syndrome). All of them but inclusion body myositis usually respond to immunomodulatory therapy, including steroids, immunosuppressive drugs, and intravenous immunglobulins. However, most often they are chronic diseases with relapses and therapeutic failure.
Authier
François-Jérôme
FJ
Centre de référence des maladies neuromusculaires Garches-Necker-Mondor-Hendaye, groupe hospitalier Albert-Chenevier-Henri-Mondor AP-HP 94010 Créteil, France. francois-jerome.authier@hmn.aphp.fr
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000328:Adult; D001327:Autoimmune Diseases / Q000175:diagnosis / Q000628:therapy; D001706:Biopsy; D004796:Clinical Enzyme Tests; D003402:Creatine Kinase / Q000097:blood; D003882:Dermatomyositis / Q000175:diagnosis / Q000473:pathology; D003937:Diagnosis, Differential; D004576:Electromyography; D005194:Family Practice; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008279:Magnetic Resonance Imaging; D018482:Muscle, Skeletal / Q000473:pathology; D009220:Myositis / Q000175:diagnosis / Q000276:immunology / Q000473:pathology / Q000628:therapy
D000305:Adrenal Cortex Hormones; D016756:Immunoglobulins, Intravenous; D007166:Immunosuppressive Agents; D003402:Creatine Kinase